TD Asset Management Inc. decreased its stake in shares of Accuray Inc. (NASDAQ:ARAY) by 3.4% during the second quarter, Holdings Channel reports. The fund owned 33,828 shares of the company’s stock after selling 1,200 shares during the period. TD Asset Management Inc.’s holdings in Accuray were worth $176,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ARAY. Advisory Services Network LLC boosted its stake in shares of Accuray by 19.0% in the second quarter. Advisory Services Network LLC now owns 21,900 shares of the company’s stock valued at $114,000 after buying an additional 3,500 shares during the last quarter. BlackRock Group LTD raised its position in Accuray by 151.9% in the first quarter. BlackRock Group LTD now owns 36,736 shares of the company’s stock valued at $212,000 after buying an additional 22,155 shares during the period. Societe Generale purchased a new position in Accuray during the second quarter valued at $331,000. SG Americas Securities LLC purchased a new position in Accuray during the second quarter valued at $331,000. Finally, California Public Employees Retirement System raised its position in Accuray by 77.8% in the second quarter. California Public Employees Retirement System now owns 105,100 shares of the company’s stock valued at $546,000 after buying an additional 46,000 shares during the period. Institutional investors and hedge funds own 92.55% of the company’s stock.

Shares of Accuray Inc. (NASDAQ:ARAY) traded up 1.61% during midday trading on Tuesday, reaching $5.68. 447,026 shares of the company traded hands. The stock’s 50-day moving average is $5.43 and its 200-day moving average is $5.43. Accuray Inc. has a 1-year low of $4.75 and a 1-year high of $7.54. The stock’s market capitalization is $463.34 million.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, August 17th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.02. The company earned $95 million during the quarter, compared to analysts’ expectations of $98.97 million. Accuray had a negative net margin of 5.55% and a negative return on equity of 35.82%. The business’s revenue for the quarter was down 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.07) earnings per share. Equities analysts predict that Accuray Inc. will post ($0.16) EPS for the current fiscal year.

Several equities analysts have recently weighed in on ARAY shares. Cowen and Company started coverage on shares of Accuray in a report on Tuesday, September 13th. They set an “outperform” rating and a $9.00 target price for the company. Morgan Stanley set a $8.00 target price on shares of Accuray and gave the company a “hold” rating in a report on Thursday, August 18th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $8.55.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy.

5 Day Chart for NASDAQ:ARAY

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Inc. (NASDAQ:ARAY).

Receive News & Ratings for Accuray Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Inc. and related companies with MarketBeat.com's FREE daily email newsletter.